Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 5, 2013, Pages 406-412

  Maeda, Sayaka ^a   Matsui, Takanori ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGEs; Diabetic nephropathy; RAGE; ROS; SGLT2

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SODIUM GLUCOSE COTRANSPORTER 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TUBULE CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGES; DIABETIC NEPHROPATHY; RAGE; ROS; SGLT2;

ANTIOXIDANTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DIABETIC NEPHROPATHIES; FLOW CYTOMETRY; GENE SILENCING; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; KIDNEY TUBULES, PROXIMAL; MICROSCOPY, CONFOCAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84880024193     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2407     Document Type: Article

References (35)

1. Yamagishi S, Fukami K, Ueda S, et al. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-959.
2. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151.
3. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3: 101-108.
4. Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients withproteinuria. Diabetes 1994; 43: 1046-1051.
5. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 464-475.
6. Vlassara H, Bucala R. Recent progress inadvanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes Suppl 1996; 3: S65-S66.
7. Brownlee M, Cerami A, Vlassara A. Advancedglycosylation end products intissue and the biochemical basis of diabetic complications. N Engl J Med 1998; 318: 1315-1321.
8. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 2007; 48: 147-157.
9. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63:464-473.
10. Matsui T, Yamagishi S, Takeuchi M, et al. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro bysuppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61: 34-39.
11. Matsui T, Yamagishi S, Takeuchi M, et al. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2010; 398: 326-330.
12. Maeda S, Matsui T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy bysuppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011; 63:241-248.
13. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development ofglomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
14. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268.
15. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
16. +/glucose cotransporters in renal proximal tubule cells. Kidney Int 2007; 72: 527-535.
17. +-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am JPhysiol Cell Physiol 2012; 302: C1174-C1188.
18. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141.
19. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
20. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391: 1405-1408.
21. Yoshida Y, Yamagishi S, Matsui T, et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009; 25: 678-686.
22. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315.
23. Brezniceanu ML, Lau CJ, Godin N, et al. Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol 2010; 2: 943-954.
24. White KE, Marshall SM, Bilous RW. Prevalence of atubular glomeruli in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2008; 23: 3539-3545.
25. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
26. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-129.
27. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-109.
28. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434.
29. Brezniceanu ML, Liu F, Wei CC, et al. Attenuation of interstitial fibrosis andtubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008; 57: 451-459.
30. Takeuchi M, Makita Z, Yanagisawa K, et al. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 1999; 5: 393-405.
31. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Compl 2003; 17:16-21.
32. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-F167.
33. Barbosa Júnior Ade A, Zhou H, Hültenschmidt D, et al. Inhibition of cellular autophagy in proximal tubular cells of the kidney in streptozotocin-diabetic and uninephrectomized rats. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 61: 359-366.
34. Kitada M, Takeda A, Nagai T, et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011; 2011: 908185. doi:10.1155/2011/908185.
35. Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013; 124: 153-164.